JP2018518465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518465A5 JP2018518465A5 JP2017557068A JP2017557068A JP2018518465A5 JP 2018518465 A5 JP2018518465 A5 JP 2018518465A5 JP 2017557068 A JP2017557068 A JP 2017557068A JP 2017557068 A JP2017557068 A JP 2017557068A JP 2018518465 A5 JP2018518465 A5 JP 2018518465A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- cells
- composition according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021099845A JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155966P | 2015-05-01 | 2015-05-01 | |
| US62/155,966 | 2015-05-01 | ||
| US201562217419P | 2015-09-11 | 2015-09-11 | |
| US62/217,419 | 2015-09-11 | ||
| US201562237942P | 2015-10-06 | 2015-10-06 | |
| US62/237,942 | 2015-10-06 | ||
| PCT/US2016/026232 WO2016178779A1 (en) | 2015-05-01 | 2016-04-06 | Methods of mediating cytokine expression with anti ccr4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099845A Division JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518465A JP2018518465A (ja) | 2018-07-12 |
| JP2018518465A5 true JP2018518465A5 (enExample) | 2020-11-12 |
| JP6956639B2 JP6956639B2 (ja) | 2021-11-02 |
Family
ID=55795197
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557068A Active JP6956639B2 (ja) | 2015-05-01 | 2016-04-06 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
| JP2021099845A Active JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099845A Active JP7203904B2 (ja) | 2015-05-01 | 2021-06-16 | 抗ｃｃｒ４抗体を用いてサイトカイン発現を媒介する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10556956B2 (enExample) |
| EP (1) | EP3288977B1 (enExample) |
| JP (2) | JP6956639B2 (enExample) |
| KR (1) | KR20170138556A (enExample) |
| CN (1) | CN107849134B (enExample) |
| AU (1) | AU2016258742B9 (enExample) |
| NZ (1) | NZ736863A (enExample) |
| WO (1) | WO2016178779A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101510065B1 (ko) * | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| AU2019387566A1 (en) | 2018-11-30 | 2021-06-17 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptor factories and methods of use thereof |
| WO2020252472A2 (en) | 2019-06-14 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Antibodies against muc1 and methods of use thereof |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2024141063A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗rsv病毒抗体、组合物、制剂及其应用 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA152990A (en) | 1913-09-02 | 1914-01-06 | Percy W. Tooth | Rule pocket |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US8962806B2 (en) * | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2013166500A1 (en) * | 2012-05-04 | 2013-11-07 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
| AU2015328273B2 (en) | 2014-10-06 | 2020-09-17 | Dana-Farber Cancer Institute, Inc. | Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof |
-
2016
- 2016-04-06 NZ NZ736863A patent/NZ736863A/en unknown
- 2016-04-06 KR KR1020177033937A patent/KR20170138556A/ko active Pending
- 2016-04-06 JP JP2017557068A patent/JP6956639B2/ja active Active
- 2016-04-06 WO PCT/US2016/026232 patent/WO2016178779A1/en not_active Ceased
- 2016-04-06 US US15/571,202 patent/US10556956B2/en active Active
- 2016-04-06 AU AU2016258742A patent/AU2016258742B9/en active Active
- 2016-04-06 CN CN201680039232.5A patent/CN107849134B/zh active Active
- 2016-04-06 EP EP16717526.4A patent/EP3288977B1/en active Active
-
2020
- 2020-02-10 US US16/786,798 patent/US11261256B2/en active Active
-
2021
- 2021-06-16 JP JP2021099845A patent/JP7203904B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| JP2020103301A5 (enExample) | ||
| JP2022532490A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| JP7041439B2 (ja) | 固形がんの治療剤 | |
| JP2022159548A5 (enExample) | ||
| JP2020528750A (ja) | 抗ｃｔｌａ−４抗体およびその使用 | |
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| JP2015527070A5 (enExample) | ||
| JP2016525117A5 (enExample) | ||
| US12312409B2 (en) | Bispecific CD137-binding antibodies for T-cell activation | |
| Schlereth et al. | Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 | |
| US20250092127A1 (en) | IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer | |
| JP2021531813A (ja) | キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用 | |
| US20230183379A1 (en) | Bispecific antibody targeting transferrin receptor 1 and soluble antigen | |
| AU2021398976B2 (en) | Multispecific antibodies for the treatment of cancer | |
| JP7566923B2 (ja) | 抗ｇｉｔｒ抗体およびその使用 | |
| JP2026508608A (ja) | メラノーマの治療における有効性の増強のためのｐｄ－１阻害剤及びｌａｇ－３阻害剤の組み合わせ | |
| CN117425492A (zh) | 双特异性t细胞接合剂的给药 | |
| Chen et al. | A trispecific T cell engager CD19xCD3xCD28 induces potent tumor-directed T cell activation and antitumor activity by simultaneously engagement of TCR and a co-stimulatory receptor CD28 | |
| CN116194142A (zh) | 通过施用pd-1抑制剂治疗癌症疼痛的方法 | |
| RU2020132497A (ru) | Связывающиеся с pd-1 антитела и способы их применения | |
| EA049485B1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| NZ769571A (en) | Antibodies binding pd-1 and uses thereof |